Odyssey Therapeutics
ODTX
73 hedge funds and large institutions have $838M invested in Odyssey Therapeutics in 2026 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 8 closing their positions.
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
139% more capital inflows, than outflows
Capital inflows: $115M | Capital outflows: $48.1M
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
24% more funds holding
Funds holding: 59 → 73 (+14)
6.14% more ownership
Funds ownership: 72.65% → 78.78% (+6.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MPM BioImpact
Boston,
Massachusetts
|
+$27.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.5M |
| 3 |
BlackRock
New York
|
+$19.2M |
| 4 |
Woodline Partners
San Francisco,
California
|
+$12M |
| 5 |
Affinity Asset Advisors
New York
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Logos Global Management
San Francisco,
California
|
-$9.8M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$7.37M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.9M |
| 4 |
Boxer Capital Management
San Diego,
California
|
-$5.15M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$4.16M |
ODTX Hedge Fund Activity: Q3 2026 in Review
73 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Odyssey Therapeutics (ODTX) for Q3 2026, worth a combined $838M — up 28% from $653M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ODTX positions and 8 closed out — a net gain of 14 holders — while 21 added to existing stakes and 13 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $27.4M. The largest seller was Logos Global Management, exiting entirely with an estimated $9.8M sold.
- 73 institutional investors held Odyssey Therapeutics (ODTX) as of Q3 2026, up from 59 in Q2 2026.
- Funds reported $838M of Odyssey Therapeutics stock for Q3 2026, up 28% quarter-over-quarter.
- 22 funds opened new Odyssey Therapeutics positions in Q3 2026 and 8 closed out, a net change of +14 holders.
- The largest Odyssey Therapeutics buyer in Q3 2026 was MPM BioImpact, an estimated $27.4M added.
- The largest Odyssey Therapeutics seller in Q3 2026 was Logos Global Management, an estimated $9.8M sold.
Based on aggregated 13F filings for Q3 2026.